Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Short Interest Update

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) saw a significant drop in short interest in the month of August. As of August 31st, there was short interest totalling 10,000 shares, a drop of 30.1% from the August 15th total of 14,300 shares. Based on an average daily trading volume, of 39,700 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.3% of the company’s shares are sold short.

Protagenic Therapeutics Price Performance

Shares of NASDAQ:PTIX traded up $0.01 during mid-day trading on Monday, reaching $0.80. 233,426 shares of the company were exchanged, compared to its average volume of 90,683. Protagenic Therapeutics has a 1 year low of $0.50 and a 1 year high of $1.98. The firm’s 50-day simple moving average is $0.70 and its 200 day simple moving average is $1.08. The firm has a market cap of $3.56 million, a price-to-earnings ratio of -0.58 and a beta of 0.26.

Protagenic Therapeutics (NASDAQ:PTIX) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.36) EPS for the quarter.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.